Marketing-authorisation holder
Takeda Pharmaceuticals U.S.A.
69 medicines in 2 countries, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
69 medicines in 2 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 69
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Advate1500iu · For Injection | Antihemophilic factor plasma/albumin free method | United States | Marketed | 2003 |
| Advate4,000iu · For Injection | Antihemophilic factor plasma/albumin free method | United States | Marketed | 2012 |
| Advate2000iu · For Injection | Antihemophilic factor plasma/albumin free method | United States | Marketed | 2006 |
| Advate3000iu · For Injection | Antihemophilic factor plasma/albumin free method | United States | Marketed | 2007 |
| Advate250iu · For Injection | Antihemophilic factor plasma/albumin free method | United States | Marketed | 2003 |
| Advate1000iu · For Injection | Antihemophilic factor plasma/albumin free method | United States | Marketed | 2003 |
| Advate500iu · For Injection | Antihemophilic factor plasma/albumin free method | United States | Marketed | 2003 |
| Adynovate250iu · For Injection | Antihemophilic factor | United States | Marketed | 2015 |
| Adynovate2000iu · For Injection | Antihemophilic factor | United States | Marketed | 2015 |
| Adynovate500iu · For Injection | Antihemophilic factor | United States | Marketed | 2015 |
| Adynovate1500iu · For Injection | Antihemophilic factor | United States | Marketed | 2016 |
| Adynovate3000iu · For Injection | Antihemophilic factor | United States | Marketed | 2017 |
| Adynovate1000iu · For Injection | Antihemophilic factor | United States | Marketed | 2015 |
| Adynovate750iu · For Injection | Antihemophilic factor | United States | Marketed | 2016 |
| ADZYNMA1500iu · For Injection | Adamts recombinant | United States | Marketed | 2023 |
| ADZYNMA500iu · For Injection | Adamts recombinant | United States | Marketed | 2023 |
| Aralast, Aralast Np0.5g · For Injection | Alfa1 antitrypsin | United States | Marketed | 2002 |
| Aralast, Aralast Np1.0g · For Injection | Alfa1 antitrypsin | United States | Marketed | 2002 |
| Autoplex, Feiba Nf, Feiba Vh1000iu · For Injection | Factor viii inhibitor bypassing activity | United States | Not marketed | 1979 |
| Autoplex, Feiba Nf, Feiba Vh500u · For Injection | Factor viii inhibitor bypassing activity | United States | Marketed | 2000 |
| Autoplex, Feiba Nf, Feiba Vh1000u · For Injection | Factor viii inhibitor bypassing activity | United States | Marketed | 2000 |
| Autoplex, Feiba Nf, Feiba Vh500iu · For Injection | Factor viii inhibitor bypassing activity | United States | Not marketed | 1979 |
| Autoplex, Feiba Nf, Feiba Vh2500u · For Injection | Factor viii inhibitor bypassing activity | United States | Marketed | 2005 |
| Bioclate (Armour), Recombinate1500iu · For Injection | Antihemophilic factor | United States | Marketed | 2010 |
| Bioclate (Armour), Recombinate1000iu · For Injection | Antihemophilic factor | United States | Marketed | 1992 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 67 | 67 | 0 | CompaniesAll medicines |
| Canada | 2 | 2 | 0 | CompaniesAll medicines |
Also in the registers of Brazil
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.